HealthEquity, Inc. (BMV:HQY)
Mexico · Delayed Price · Currency is MXN | Market Cap | 126.72B -18.5% |
| Revenue (ttm) | 22.78B +9.5% |
| Net Income | 3.73B +122.5% |
| EPS | 42.66 +125.7% |
| Shares Out | n/a |
| PE Ratio | 33.95 |
| Forward PE | 18.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28 |
| Average Volume | 5 |
| Open | 2,150.00 |
| Previous Close | 2,020.00 |
| Day's Range | 2,150.00 - 2,150.00 |
| 52-Week Range | 1,570.00 - 2,150.00 |
| Beta | n/a |
| RSI | 74.28 |
| Earnings Date | May 28, 2026 |
About HealthEquity
HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. It offers health savings accounts (HAS); investment platform; online-only automated investment advisory services through Advisor, a Web-based tool. The company also provides flexible spending accounts (FSA) for health and dependent care; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. In addition, the company offer... [Read more]
Financial Performance
In fiscal year 2026, HealthEquity's revenue was $1.31 billion, an increase of 9.47% compared to the previous year's $1.20 billion. Earnings were $215.20 million, an increase of 122.54%.
Financial numbers in USD Financial StatementsNews
HealthEquity Proxy statement: Proxy filing
HealthEquity filed a proxy statement on May 13, 2026, providing details for shareholder voting and corporate governance matters.
HealthEquity Proxy statement: Proxy filing
HealthEquity filed a proxy statement on May 13, 2026, providing details for shareholder voting and corporate governance matters.
HealthEquity Announces First Quarter Earnings Release Date and Investor Conference Schedule
DRAPER, Utah, May 05, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent health savings account (HSA) custodian by account volume and ...
Optum acquisition not near-term threat to HealthEquity, says BofA
BofA notes that UnitedHealth (UNH), announced that the company entered into a definitive agreement to acquire Alegeus Technologies, an adjunct competitor to HealthEquity (HQY). Alegeus offers a white-...
HealthEquity management to meet with KeyBanc
Meeting to be held in Minneapolis on April 17 hosted by KeyBanc.
HealthEquity upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Sean Dodge upgraded HealthEquity (HQY) to Outperform from Market Perform with a price target of $105, up from $85. The firm says recent developments increase its conviction…
HealthEquity Chief Technology Officer to be terminated without cause
On April 6, HealthEquity (HQY) announced that the employment of Eli Rosner, the Company’s Chief Technology Officer, will be terminated by the Company without cause, effective April 17, 2026. Sunil…
HealthEquity Appoints Sanford Health CEO Bill Gassen to Board of Directors
DRAPER, Utah, March 30, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent health savings account (HSA) custodian by account volume an...
HealthEquity price target raised to $128 from $120 at Deutsche Bank
Deutsche Bank raised the firm’s price target on HealthEquity (HQY) to $128 from $120 and keeps a Buy rating on the shares. The firm says the company’s visibility and execution…
HealthEquity price target lowered to $110 from $125 at Barrington
Barrington lowered the firm’s price target on HealthEquity (HQY) to $110 from $125 and keeps an Outperform rating on the shares following the Q4 report. The company topped expectations and…
HealthEquity price target lowered to $100 from $110 at RBC Capital
RBC Capital lowered the firm’s price target on HealthEquity (HQY) to $100 from $110 but keeps an Outperform rating on the shares after its Q4 earnings beat and guidance raise.
HealthEquity price target lowered to $123 from $129 at JPMorgan
JPMorgan lowered the firm’s price target on HealthEquity (HQY) to $123 from $129 and keeps an Overweight rating on the shares. The company reported a Q4 beat and fiscal 2027…
HealthEquity Earnings Call Transcript: Q4 2026
Fiscal 2026 delivered record HSA sales, strong revenue and margin growth, and robust shareholder returns. AI and digital initiatives drove operational efficiency, while new legislation expanded the addressable market. Fiscal 2027 guidance was raised, reflecting continued momentum.
HealthEquity Annual report: Q4 2026
HealthEquity has published its Q4 2026 annual report on March 17, 2026.
HealthEquity Earnings release: Q4 2026
HealthEquity released its Q4 2026 earnings on March 17, 2026, summarizing the period's financial results.
HealthEquity reports Q4 EPS 95c, consensus 90c
Reports Q4 revenue $334.6M, consensus $332.82M. “We are raising our fiscal 2027 guidance after delivering record new HSAs from sales and significant margin expansion,” said Scott Cutler, president and...
HealthEquity sees FY27 EPS $4.56-$4.65, consensus $4.54
Sees FY27 revenue $1.41B-$1.42B, consensus $1.41B. Sees FY27 adjusted EBITDA $618M-$628M. The company said, “For the fiscal year ending January 31, 2027, management expects revenues of $1.405 billion ...
HealthEquity Reports Record Revenue, Earnings and New HSAs From Sales for Fourth Quarter and Year Ended January 31, 2026, Resulting in Raised Fiscal 2027 Outlook
Highlights of the fiscal year include: Revenue increased 9% to $1.31 billion. Net income increased 123% to $215.2 million, and net income margin increased to 16% from 8% last year.
Notable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Lululemon (LULU), consensus $4.78… Oklo (OKLO), consensus (16c)… HealthEquity (HQY), consensus 44c.
HealthEquity price target lowered to $85 from $100 at BMO Capital
BMO Capital lowered the firm’s price target on HealthEquity (HQY) to $85 from $100 and keeps a Market Perform rating on the shares. The firm believes that the company will…
HealthEquity price target lowered to $108 from $120 at Jefferies
Jefferies lowered the firm’s price target on HealthEquity (HQY) to $108 from $120 and keeps a Buy rating on the shares. Pre-released Q4 operational metrics show “strong” HSA account growth…
HealthEquity price target lowered to $110 from $118 at Barclays
Barclays analyst Peter Warendorf lowered the firm’s price target on HealthEquity (HQY) to $110 from $118 and keeps an Overweight rating on the shares. The company preannounced Q4 results “near…
HealthEquity backs FY26 EPS view $3.87-$3.95, consensus $3.95
Backs FY26 revenue view $1.3B-$1.31B, consensus $1.31B. Backs FY26 adjusted EBITDA view $555M-$565M. The company said, “HealthEquity (HQY) reaffirmed its previously provided outlook for the fiscal yea...
HealthEquity backs FY27 revenue view $1.38B-$1.41B, consensus $1.41B
The company said, “HealthEquity (HQY) reaffirmed its previously provided outlook for the fiscal year that ended January 31, 2026, and the fiscal year ending January 31, 2027. The Company expects…
HealthEquity reports HSAs as of January 31 10.6M, up 7%
HealthEquity (HQY) announced its HSAs, HSA assets, and total accounts as of its fiscal year ended January 31. The total number of HSAs as of January 31 was 10.6M, an…